Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand.
School of Pharmacy, Southwest Medical University, Luzhou, China.
Eur J Cancer Prev. 2024 Jul 1;33(4):334-346. doi: 10.1097/CEJ.0000000000000859. Epub 2023 Nov 13.
Carcinoembryonic antigen (CEA) is a broad-spectrum tumor marker for differential diagnosis, monitoring, and response assessment of a variety of malignancies. This meta-analysis was aimed at evaluating whether serum CEA could predict the prognosis in patients with colorectal cancer liver metastasis (CRCLM) before and after liver resection (LR).
PubMed, Embase, Cochrane, and Web of Science were systematically searched to retrieve literature, with a search cutoff date of 27 February 2023. Articles were strictly screened for inclusion according to pre-specified inclusion and exclusion criteria. Data were pooled and analyzed using Stata 16.0.
This meta-analysis included 36 studies involving a total of 11 143 CRCLM patients. The results showed that a high pre-LR serum CEA level was correlated with poor overall survival (OS: HR = 1.61, 95% CI = 1.49-1.75, P < 0.001) and recurrence-free survival (RFS: HR = 1.27, 95% CI = 1.11-1.45, P < 0.001) in CRCLM patients. A high post-LR serum CEA level predicted poor overall survival (OS: HR = 2.66, 95% CI = 2.10-3.38, P < 0.001).
High preoperative and postoperative serum CEA levels in patients with CRCLM were significantly associated with poor prognosis, independent of treatment modality, mode of analysis, case origin, and cutoff value classification.
癌胚抗原（CEA）是一种广谱肿瘤标志物，可用于鉴别诊断、监测和评估多种恶性肿瘤的反应。本荟萃分析旨在评估血清 CEA 能否预测结直肠癌肝转移（CRCLM）患者肝切除（LR）前后的预后。
系统检索 PubMed、Embase、Cochrane 和 Web of Science 以检索文献，检索截止日期为 2023 年 2 月 27 日。根据预先设定的纳入和排除标准严格筛选纳入的文献。使用 Stata 16.0 对数据进行汇总和分析。
本荟萃分析纳入了 36 项研究，共纳入 11143 例 CRCLM 患者。结果表明，LR 前高血清 CEA 水平与总生存期（OS：HR=1.61，95%CI=1.49-1.75，P<0.001）和无复发生存期（RFS：HR=1.27，95%CI=1.11-1.45，P<0.001）较差相关。LR 后高血清 CEA 水平预示着总生存期（OS：HR=2.66，95%CI=2.10-3.38，P<0.001）较差。
CRCLM 患者术前和术后高血清 CEA 水平与预后不良显著相关，与治疗方式、分析模式、病例来源和截断值分类无关。
